YM BioSciences Inc. (YMI, YM.TO) said that Cytopia has commenced enrollment of a phase I/II trial evaluating CYT387.
The dose-escalation phase I/II study is investigating the safety and tolerability of CYT387 administered as a daily oral capsule dose in 30-60 patients with myelofibrosis, a disorder within a family of hematological conditions known as myeloproliferative neoplasms.
The study will also allow preliminary assessment of the compound's activity in these patients including its effect on spleen size, hematological symptoms, quality-of-life and markers of aberrant JAK2 activity in blood.
The trial is being conducted at Mayo Clinic in Rochester, Minnesota.
A proposal to merge Cytopia into YM is pending approval by Cytopia shareholders, Australian court and other regulatory approvals.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.